2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations

P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations

Back to course

Pdf Summary

The TRITON study (NCT06008093) aims to evaluate the efficacy of a combination treatment of tremelimumab, durvalumab, and chemotherapy versus pembrolizumab and chemotherapy in patients with metastatic non-squamous non-small-cell lung cancer (NSCLC) who have mutations in the STK11, KEAP1, and/or KRAS genes. The study is sponsored by AstraZeneca and is currently ongoing, with completion anticipated by August 2027.<br /><br />This phase 3b clinical trial arose from findings from the POSEIDON trial, which suggested significant improvements in overall survival (OS) with the use of tremelimumab and durvalumab combined with chemotherapy compared to chemotherapy alone, especially in patients with specific genetic mutations such as STK11, KEAP1, and KRAS. The TRITON trial will further investigate this combination therapy as a first-line treatment option for this subgroup of patients, who are known to have poorer responses to other immunotherapies.<br /><br />Participants in the TRITON study will be randomly assigned to receive either tremelimumab with durvalumab and chemotherapy or pembrolizumab with chemotherapy. The primary measure of efficacy will be overall survival, with additional assessments on progression-free survival, response rate, and safety. Eligibility for the study includes patients with treatment-naive, EGFR/ALK wild-type metastatic NSCLC with non-squamous histology, and specific genetic mutations, among other criteria.<br /><br />This research is particularly important due to the poor prognosis associated with these specific genetic mutations affecting the tumor microenvironment, making standard treatments less effective. By exploring this biomarker-driven approach, the study aims to offer new insights into personalized treatment strategies for patients with these challenging cancer subtypes. More information can be accessed on the ClinicalTrials.gov website.

Asset Subtitle

Stephen Liu

Meta Tag

Speaker Stephen Liu

Topic Metastatic NSCLC – Immunotherapy

Keywords

TRITON study

NCT06008093

tremelimumab

durvalumab

chemotherapy

pembrolizumab

NSCLC

STK11 mutations

KEAP1 mutations

KRAS mutations